Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 0.48 |
| ▸ | CA2 | P00918 | 14/20 | 0.48 |
| ▸ | CA7 | P43166 | 6/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 6/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA3 | P07451 | 3/20 | 0.48 |
| ▸ | CA4 | P22748 | 3/20 | 0.48 |
| ▸ | CA6 | P23280 | 3/20 | 0.48 |
| ▸ | CA5A | P35218 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11929094 | 0.88 | CA1 (0.49) | CA1CA2CA7CA13CA12 | |
| Zidapamide SCHEMBL2109204 | 0.77 | CA1 (0.63) | CA1CA2CA7CA13CA12 | |
| SCHEMBL11929295 | 0.74 | CA1 (0.50) | CA1CA2CA7CA13CA12 | |
| SCHEMBL10281261 | 0.74 | CA1 (0.44) | CA1CA2CA7CA13CA12 | |
| SCHEMBL9352647 | 0.71 | CA1 (0.61) | CA1CA2CA7CA13CA12 | |
| SCHEMBL9772385 | 0.69 | SIGMAR1 (0.47) | CA1CA2CA7CA13CA12 | |
| SCHEMBL7962240 | 0.69 | SIGMAR1 (0.47) | CA1CA2CA7CA13CA12 | |
| SCHEMBL11560883 | 0.68 | CA1 (0.55) | CA1CA2CA7CA13CA12 | |
| SCHEMBL20647013 | 0.65 | CA1 (0.62) | CA1CA2CA7CA13GAA | |
| SCHEMBL10589942 | 0.65 | CA1 (0.54) | CA1CA2CA7CA13CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-20160024011-A1 | Multi-API Loading Prodrugs | ALKERMES PHARMA IRELAND LTD (IE) | 2016-01-28 | — | — | US | disclosed |
| US-20120202823-A1 | Multi-API Loading Prodrugs | ALKERMES, INC. | 2012-08-09 | — | — | US | disclosed |
| WO-2012088441-A1 | MULTI- API LOADING PRODRUGS | ALKERMES, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024011-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | CA1 770/4885CA2 535/4885CA7 155/4885 |
| US-20120202823-A1 | Multi-API Loading Prodrugs | AADAC, PAICS, ABCG2 | CA1 770/4885CA2 535/4885CA7 155/4885 |
| US-20180194732-A1 | MULTI-API LOADING PRODRUGS | AADAC, PAICS, ABCG2 | CA1 770/4885CA2 535/4885CA7 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.